What happens at an FDA advisory committee meeting

An FDA advisory committee meeting, usually shortened to "AdComm", is a public meeting where outside experts review a drug application and give the FDA their advice. It is the only point in a drug review where the FDA's thinking is aired in public before the decision, which is why the meeting, and especially the documents released two days before it, get so much attention.

What an advisory committee is

The FDA has standing committees organised by therapeutic area, such as the Oncologic Drugs Advisory Committee, the Cardiovascular and Renal Drugs Advisory Committee, and the Cellular, Tissue, and Gene Therapies Advisory Committee. They operate under the Federal Advisory Committee Act and the FDA's own rules in 21 CFR Part 14.

A typical drug committee includes clinicians and researchers in the relevant field, statisticians, a consumer representative and often a patient representative, all of whom vote. There is also usually an industry representative, who takes part in the discussion but does not vote. For a particular meeting the FDA can add temporary members with specific expertise. Members are screened for financial conflicts of interest, and any waivers are posted with the meeting materials.

Why some applications get one and others don't

Most applications never go to a committee. The FDA convenes one when it wants independent input on a question it considers genuinely open: a borderline efficacy result, a new kind of safety risk, a novel endpoint, a first-of-its-kind technology, or a decision with wide public-health consequences.

For a new molecular entity, the law requires the FDA either to refer the application to an advisory committee or to explain, in its action letter, why it didn't (section 505(s) of the Federal Food, Drug, and Cosmetic Act). In practice that means many novel drugs are approved without a meeting, with the explanation written into the approval package.

A meeting is therefore a signal in itself. It says the FDA has at least one question it wants outside experts to weigh in on. It doesn't say which way the agency is leaning.

Before the meeting: the notice and the briefing documents

Meetings are announced in the Federal Register, normally at least 15 days in advance, and listed on the FDA's advisory committee calendar. Companies usually announce the date too, often months earlier, once the FDA has told them a meeting is planned.

The most important documents appear shortly before the meeting. The FDA posts its own briefing document, the company's briefing document, and the draft questions for the committee, no later than two business days before the meeting under a 2008 FDA guidance.

The FDA briefing document is the closest thing the public gets to the reviewers' view. It's written by the review team, it lays out where the agency agrees with the company's analysis and where it doesn't, and the questions at the end show exactly what the FDA is uncertain about. A document that spends most of its length on one safety signal, or on whether a single trial is enough, tells you where the meeting will go.

How the day runs

Most meetings follow the same pattern, usually over one day.

Introductions and conflict-of-interest statement. The chair opens the meeting and the FDA reads out any conflict waivers.
Company presentation. The sponsor presents its case: the disease, the unmet need, the trial results and the safety data.
FDA presentation. The review team presents its own analysis, which may reach different conclusions from the same data.
Clarifying questions. Committee members question both sides.
Open public hearing. Anyone who registered can speak, including patients, families, doctors and advocacy groups. The FDA's rules set aside at least an hour for it.
Discussion and voting. The committee works through the FDA's questions. Some are for discussion only. Others are put to a vote, typically a version of "Do the benefits of [drug] outweigh its risks for [population]?"

Votes are taken electronically and simultaneously, so members can't follow each other, and then each member explains their vote on the record. Meetings are usually webcast, and the transcript is posted afterwards.

What the vote means

The vote is advice. The FDA is not bound by it, and the final decision belongs to the agency, made by the PDUFA date in the usual way. The FDA follows most committee votes, but it has approved drugs after negative votes and rejected drugs after positive ones.

A few things are worth reading beyond the headline tally:

The exact question. A "yes" on "Is the drug effective?" is weaker than a "yes" on "Do the benefits outweigh the risks?". Sometimes the most important question isn't put to a vote at all.
The explanations. A 7–6 vote where every "yes" came with heavy caveats is not the same as a clean 7–6.
The conditions. Committees often say they'd support approval only with a narrower label, a boxed warning, a risk-management programme or a confirmatory trial. Those conditions often show up in the final approval.
The FDA's own tone on the day. How firmly the review team defends its briefing document is often as informative as the vote.

After the meeting

The company typically announces the vote the same day, often by press release furnished on Form 8-K. The decision still comes by the PDUFA date, which can be weeks or months later. If the FDA decides against approval it issues a Complete Response Letter, and, since 2025, the FDA publishes those letters too.

How AdComms appear on this site

When a company we track discloses a scheduled advisory committee meeting, it gets its own row, labelled as an AdComm, alongside the PDUFA date it precedes. The row links to the company's announcement or the FDA's calendar entry. Because the FDA calendar and the Federal Register notice are public, an AdComm date is one of the few catalyst dates you can confirm from a government source rather than the company's word.

Where to look yourself

The FDA's advisory committee calendar lists upcoming meetings with links to each meeting page, where the briefing documents, questions, webcast link and, later, the transcript and minutes are posted.

More guides

What a PDUFA date is, and why the FDA doesn't publish themThe PDUFA target action date is the FDA's own deadline for deciding on a drug application. Here is where it comes from, how it moves, and why you only hear about it from the company.
What a Complete Response Letter means, and what usually followsA Complete Response Letter is the FDA's "not yet" on a drug application. What it contains, the company's options, how resubmission clocks work, and how to read the announcement.
How to read a Phase 3 topline readoutEndpoints, p-values, effect sizes, safety tables and the phrase "met its primary endpoint": a practical guide to reading the press release a company puts out when pivotal trial results land.
Clinical trial phases explained: Phase 1 to Phase 4What each phase of clinical development is for, roughly how big the trials are, what the in-between labels like 1b, 2a and 2/3 mean, and what a readout at each stage can and can't tell you.
NDA vs BLA: the two kinds of US drug applicationWhy some products are filed as a New Drug Application and others as a Biologics License Application, who reviews each, what supplements and rolling submissions are, and why the difference matters after approval.
Fast Track, Breakthrough, Priority Review and Accelerated Approval explainedThe FDA's expedited programmes are often lumped together, but they do different things at different stages. What each one is, what it changes about the timeline, and what it doesn't promise.
How to verify a catalyst date yourself on SEC EDGARA step-by-step walkthrough of the method behind this site: finding the filing that announced a PDUFA date or readout window, reading it properly, and spotting the traps that catalyst calendars fall into.
8-K vs 6-K vs press release: where catalyst dates are disclosedWhy almost every row on this site links to an 8-K exhibit, what the 6-K is for, when a press release has no filing behind it, and how the item numbers and "furnished vs filed" affect what you're reading.
Why catalyst windows like "H2 2026" are vague, and how they narrowMost biotech catalysts don't have a date, only a window the company guided to. Why that is, what the common phrases mean, how windows tighten or slip, and how this site handles them.
Glossary of FDA and biotech catalyst termsPlain-English definitions of the regulatory, clinical and SEC-filing terms used across the tracker and the guides, from AdComm to Type A meeting.